Every material Form 8-K Context Therapeutics Inc. has filed with the SEC since June 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Context Therapeutics filed an updated corporate presentation dated August 2026 as Exhibit 99.1 to a Form 8-K on August 5, 2026, for use in meetings with investors and analysts. The filing is furnished under Regulation FD and contains no financial results, guidance, or new financing terms, and it lists the company's clinical timelines for its two T cell engager programs.
Updated corporate presentation filed as Exhibit 99.1 on August 5, 2026; the filing is furnished, not filed, under Section 18 of the Exchange Act.
CTIM-76 (Claudin 6 x CD3) has FDA Fast Track Designation for platinum-resistant ovarian cancer; the presentation anticipates starting a Phase 1b study in Q1 2027.
CT-202 (Nectin-4 x CD3) Phase 1a first patient dosing is anticipated in Q3 2026, with initial data expected in 2H 2027.
The presentation reports a 29% confirmed objective response rate in 7 RECIST-evaluable platinum-resistant ovarian cancer patients at target doses, as of May 29, 2026.
Context Therapeutics received a Nasdaq notice on July 29, 2026 stating its common stock failed to maintain a $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027 to regain compliance, and the notice has no immediate effect on its listing or trading, but failure to regain compliance could lead to delisting proceedings.
Nasdaq notice dated July 29, 2026 cites Listing Rule 5550(a)(2), the minimum bid price rule
Compliance deadline is January 25, 2027, after a 180 calendar day initial period
Company may be eligible for an additional 180-day Second Compliance Period if it meets listing requirements and notifies Nasdaq of its intent to cure
The notice has no immediate effect on the company's listing or trading
Context Therapeutics filed a press release and conference call materials on interim Phase 1a data for CTIM-76, its Claudin 6 x CD3 bispecific antibody, which the company describes as showing efficacy and safety signals in heavily pretreated patients. The sample is small (13 patients in all comers and 10 RECIST-evaluable at target doses, as of May 29, 2026), and the company states that clinical data are preliminary. The company also expects cash runway into mid-2027 and anticipates further CTIM-76 data in Q4 2026.
As of May 29, 2026, 2 of 10 RECIST-evaluable patients at target doses (140 to 280 µg) had confirmed overall response, and 5 of 10 had disease control.
Grade 1 cytokine release syndrome (CRS) was reported in 16% of all-comers patients (n=13) at target doses, with no Grade 2 or higher CRS in that group.
Updated CTIM-76 data are anticipated in Q4 2026, and preliminary Phase 1a data for the CT-95 mesothelin program are expected in September 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Context Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →